fashion -WSS

fashion

author：explore 2025-09-30 17:44:03 - browse：6

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Breakthrough Alzheimer’s drugs are inaccessible in rural states

WSS

No plane should take off without an EpiPen onboard

Childhood cancer progress stalls for Black, Hispanic kids: Report

Vertex non

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

hotspot

fashion

leisure time

Peter Hotez and the public health issue of online harassment

David Sabatini, ex

Heart attack and stroke risk calculators need revising

Does good food count as health care? Study aims to find out

Novavax promises a turnaround & Lilly roils the obesity market

NIH launches clinical trials and new research office for long Covid

Sports medicine is finally prioritizing gender equality

Vertex non

Trump demands the U.S. pay no more for drugs than other countries … again

Does good food count as health care? Study aims to find out

Wikipedia

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Morphosys mixed study results for blood cancer drug

Childhood cancer progress stalls for Black, Hispanic kids: Report

Scientists inch closer to single

hotspot

entertainment

hotspot

hotspot